Perigon Wealth Management LLC decreased its stake in shares of Bristol-Myers Squibb Company (NYSE:BMY) by 8.3% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 12,453 shares of the biopharmaceutical company’s stock after selling 1,125 shares during the period. Perigon Wealth Management LLC’s holdings in Bristol-Myers Squibb were worth $694,000 as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in BMY. Renaissance Technologies LLC increased its stake in Bristol-Myers Squibb by 108.5% during the 2nd quarter. Renaissance Technologies LLC now owns 13,488,200 shares of the biopharmaceutical company’s stock valued at $751,563,000 after buying an additional 7,020,200 shares during the period. Franklin Resources Inc. increased its stake in Bristol-Myers Squibb by 185.2% during the 2nd quarter. Franklin Resources Inc. now owns 6,098,935 shares of the biopharmaceutical company’s stock valued at $339,830,000 after buying an additional 3,960,191 shares during the period. Janus Henderson Group PLC increased its stake in Bristol-Myers Squibb by 2,990.5% during the 2nd quarter. Janus Henderson Group PLC now owns 3,634,128 shares of the biopharmaceutical company’s stock valued at $202,494,000 after buying an additional 3,516,536 shares during the period. Arrowstreet Capital Limited Partnership increased its stake in Bristol-Myers Squibb by 42,071.5% during the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 3,331,549 shares of the biopharmaceutical company’s stock valued at $185,634,000 after buying an additional 3,323,649 shares during the period. Finally, Ameriprise Financial Inc. increased its stake in Bristol-Myers Squibb by 18.7% during the 1st quarter. Ameriprise Financial Inc. now owns 15,547,051 shares of the biopharmaceutical company’s stock valued at $845,504,000 after buying an additional 2,451,390 shares during the period. 69.82% of the stock is currently owned by hedge funds and other institutional investors.

Bristol-Myers Squibb Company (NYSE:BMY) opened at $62.41 on Friday. The stock has a market cap of $101,688.18, a P/E ratio of 20.99, a PEG ratio of 2.36 and a beta of 1.18. The company has a quick ratio of 1.46, a current ratio of 1.59 and a debt-to-equity ratio of 0.47. Bristol-Myers Squibb Company has a 52 week low of $46.01 and a 52 week high of $66.10.

Bristol-Myers Squibb (NYSE:BMY) last announced its earnings results on Thursday, October 26th. The biopharmaceutical company reported $0.75 EPS for the quarter, missing the consensus estimate of $0.77 by ($0.02). Bristol-Myers Squibb had a return on equity of 32.41% and a net margin of 20.56%. The firm had revenue of $5.25 billion during the quarter, compared to analyst estimates of $5.20 billion. During the same quarter in the previous year, the business earned $0.77 earnings per share. The business’s quarterly revenue was up 6.7% compared to the same quarter last year. research analysts expect that Bristol-Myers Squibb Company will post 2.99 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Thursday, February 1st. Shareholders of record on Friday, January 5th will be issued a $0.40 dividend. This represents a $1.60 annualized dividend and a dividend yield of 2.56%. This is a boost from Bristol-Myers Squibb’s previous quarterly dividend of $0.39. The ex-dividend date is Thursday, January 4th. Bristol-Myers Squibb’s dividend payout ratio (DPR) is presently 61.42%.

Several equities analysts have commented on the stock. Vetr cut shares of Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating and set a $64.20 target price on the stock. in a research note on Tuesday, August 22nd. Citigroup set a $72.00 target price on shares of Bristol-Myers Squibb and gave the company a “buy” rating in a research note on Wednesday, October 25th. BMO Capital Markets set a $49.00 price objective on shares of Bristol-Myers Squibb and gave the stock a “sell” rating in a research note on Thursday, October 26th. Goldman Sachs Group reaffirmed a “buy” rating and issued a $65.00 price objective (up previously from $62.00) on shares of Bristol-Myers Squibb in a research note on Thursday, September 7th. Finally, Jefferies Group reaffirmed a “buy” rating and issued a $66.00 price objective (up previously from $63.00) on shares of Bristol-Myers Squibb in a research note on Thursday, August 24th. One equities research analyst has rated the stock with a sell rating, ten have given a hold rating and eleven have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average price target of $64.93.

In other Bristol-Myers Squibb news, EVP Thomas J. Jr. Lynch sold 5,300 shares of the firm’s stock in a transaction dated Tuesday, December 12th. The shares were sold at an average price of $63.24, for a total value of $335,172.00. Following the completion of the transaction, the executive vice president now directly owns 9,251 shares in the company, valued at $585,033.24. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Sandra Leung sold 156,582 shares of the firm’s stock in a transaction dated Monday, December 4th. The stock was sold at an average price of $63.37, for a total transaction of $9,922,601.34. Following the completion of the transaction, the executive vice president now owns 584,373 shares of the company’s stock, valued at $37,031,717.01. The disclosure for this sale can be found here. Company insiders own 0.23% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This article was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this article on another domain, it was illegally stolen and reposted in violation of international copyright law. The original version of this article can be read at https://www.thecerbatgem.com/2017/12/16/perigon-wealth-management-llc-sells-1125-shares-of-bristol-myers-squibb-company-bmy.html.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Stock Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related stocks with our FREE daily email newsletter.